The FBI warns the public about falsification compound Weight loss medications in the market they claim to contain SemiglutideThe active ingredient in Ozímpico and CrazyTwo prescription medications used for weight loss.
A notice On the FBI website On the other hand, they warn that fraudulent medications that seek to contain “mixtures composed of unknown drugs that do not contain semaglutida, medications with high levels of impurities and insecure or unmpected drugs.”
The health risks of carrying the “misrepresented medications” include everything from heart and gastrointestinal disorders to nervous system disorders, psychiatric disorders and death, according to the FBI.
The agency warns that “non -compliant medical care providers are selling fraudulent medications, including weight loss clinics, pharmacies and medical spas.
The semaglutida is seen in this file photo without date.
Stock Photo/Adobe Stock
In an example, the FBI says that a medical spa clinic and weight loss in the South sold its own compound compound to weight that was found that contained animal degree semaglutida with vitamin B12, not reaching regulations established by the Food and Medicines Administration of the United States.
The FBI says that consumers must observe and avoid “suspiciously low prices” of medicines to lose weight sold by medical care suppliers without a license and must buy medications only from licensed pharmacies.
The agency also says that patients should consult with a medical provider before using any medicine for weight loss.
The legitimate versions of compound medications are copies of medicines approved by the FDA made by licensed pharmacies and are not approved or inspected by the FDA.
The drug compound is allowed when the medications are on the FDA scarcity list, or in circumstances in which a patient cannot take a version of a medication performed by a pharmaceutical company and needs an alternative. Semaglutid compound versions require a recipe.
An increase in the popularity of medicines used for weight loss in recent years led to drug scarcity. The FDA recently declared the “resolved” shortage, eliminating drugs, including Ozempic and Wogovy from its scarcity list.
The FDA later announced A timeline for when most compound versions can no longer be made.
State license pharmacies should stop making more compound semaglutida (copies of Wegovy and Ozempic) of Novo Nordisk) before April 22, and larger outsourcing pharmacies before May 22, waiting for any judicial decision.
Ozempic is approved by the FDA to treat type 2 diabetes, but some doctors recipe the “out of label” medication for weight loss, as allowed by FDA.
Wegovy contains the same main ingredient as Ozempico, Semaglutida, and is approved by FDA for weight loss in people with obesity or who are overweight with at least one condition related to weight. It is also approved to reduce the risk of important cardiovascular events in adults with obesity or that are overweight with established cardiovascular disease.
The semaglutida works slowing down the movement of food through the stomach and braking the appetite, which causes weight loss.
